products through the induction of endog-
enous pyrogens was thought to play a cen-
tral role. Later, IL-1 was shown to be a major
component of such endogenous pyrogens,
and therefore it can be speculated that the
IL-9–potentiating properties of IL-1 rep-
resent one of the main antitumor activities
of such vaccines. However, IL-9 was also
shown to support the growth of tumors
that express IL-9 receptors, indicating an
ambivalent role of this cytokine in tumor
immunology (10, 11). Hence, inflammation
and in particular distinct pro-inflammatory
cytokines may provoke a Janus-faced
response depending on the expression of
the respective cytokine receptor by tumor
cells. This ambivalence implicitly requires
a detailed genetic and immunological charac-
terization of each individual tumor and/or
patient to develop personalized innova-
tive therapeutic strategies in cancer
immunotherapy.

Address correspondence to: Tobias Bopp,
Institute for Immunology, Molecular Immu-
nology, University Medical Centre of the
Johannes Gutenberg University Mainz,
Mainz, Germany. Phone: 0049.0.6131.176175;
Fax: 0049.0.6131.176202; E-mail: boppt@uni-
mainz.de.

1. Dougan M, Dranoff G. Immune therapy for cancer. 
2. Leek RD, et al. Association of macrophage infiltration
   with angiogenesis and prognosis in invasive breast
3. Ribatti D, et al. Tumor vascularity and tryptase-
   positive mast cells correlate with a poor prognosis
correlates of anti-IP-1 antibody in cancer. *N Engl
5. Hodi FS, et al. Improved survival with ipilimumab
   in patients with metastatic melanoma. *N Engl J
7. Purwar R, et al. Robust tumor immunity to mela-
noma mediated by interleukin-9-producing T cells
[published online ahead of print: July 8, 2012]. *Nat
Med*. doi:10.1038/nm.2856.
8. Seassen M, Schmitt E, Bopp T. From interleukin-9 to
cutaneous malignant melanoma in melanoma-
prone families with and without CDKN2A muta-
11. Knoops L, Renaud J-C. IL-9 and its receptor: from
signal transduction to tumorigenesis. *Growth Fac-
12. Levitt RC, et al. IL-9 pathway in asthma: new thera-
pic targets for allergic inflammatory disorders.
13. Staudt V, et al. Interferon-regulatory factor 4 is es-
sential for the developmental program of T help-
required for the development of IL-9-producing
T cells and allergic inflammation. *Nat Immunol*.
15. Zhou Y, et al. IL-9 promotes Th17 cell migration
   into the central nervous system via CC chemo-
2011;186(7):4415–4421.
16. Ye ZJ, et al. Differentiation and recruitment of
   Th9 cells stimulated by pleural mesothelial cells
   in human Mycobacterium tuberculosis infection.
17. Smith SE, Hoelzinger DB, Dominguez AL, Van
Snick J, Lustgarten J. Signals through 4-1BB inhibit
T regulatory cells by blocking IL-9 production
enhancing antitumor responses. *Cancer Immunol
Immunother*. 2011;60(12):1775–1787.
18. Heib V, et al. Mast cells are crucial for early inflam-
mation, migration of Langerhans cells, and CTL
responses following topical application of TLR7
19. Schmidt E, et al. IL-1-I serves as a secondary signal for
20. Naus NC, Swift WE, Coley BL. The treatment of
malignant tumors by bacterial toxins as developed by
the late William B. Coley, MD, reviewed in the light

Hypertension occurs in approximately 30% of individuals in Western popula-
ations and is known to be a major cause of stroke, heart failure, and myo-
cardial infarction. Despite this, the molecular etiology of hypertension
remains poorly understood. In this issue of the *JCI*, Young et al. show that
endoplasmic reticulum (ER) stress is an essential signaling event for angio-
tensin II–induced hypertension in cells of the central nervous system. This
provides new insight into the molecular mechanisms that drive hyperten-
sion and suggests a potential target for future therapy.

In 1940, Irvine Page described a crystalline
substance purified from the reaction of
renin and renin activator, which he named
angiotinon (1). Simultaneously, Braun-
Menendez and coworkers identified a simi-
lar substance, which they called hypertensin
(2). It is remarkable that three-quarters of a
century later, we are still learning the actions
of this molecule that ultimately came to be
known as angiotensin II. It is now under-
stood that this octapeptide has pleiotropic
actions, including promotion of renal tubu-
lar sodium reuptake, aldosterone release,
vasoconstriction, vascular remodeling, car-
diac hypertrophy, cellular oxidative stress,
and inflammation. Ongoing research is
constantly refining and expanding this list.

Conflicts of interest: The authors have declared that no
conflict of interest exists.

Citation for this article: *J Clin Invest*. 2012;
122(11):3859–3861. doi:10.1172/JCI65173.

Endoplasmic reticulum stress and hypertension —
a new paradigm?

Alyssa H. Hasty1 and David G. Harrison2

1Department of Molecular Physiology and Biophysics and Division of Clinical Pharmacology, and 2Department of Medicine,
Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Commentaries

vasculosum of the lamina terminals, and the area postrema (Figure 1). The predominant CNS effects of angiotensin II are to increase sympathetic outflow, promote vasopressin release, and stimulate thirst.

A central role for angiotensin II
Angiotensin II promotes renal sodium reabsorption, adrenal aldosterone production, and vasoconstriction, all of which promote blood pressure elevation. In addition to these peripheral actions, substantial data indicate that the central effects of angiotensin II are also essential for the development of hypertension. Lesions in the anteroventral third ventricle (AV3V) region, which includes the inferior aspects of the lamina terminals, prevent most forms of experimental hypertension (5). Intracerebroventricular injections of angiotensin II cause neuronal activation in the circumventricular organs, and these effects are blocked by angiotensin II receptor type 1 (AT1) antagonists (6). The SFO directly projects to the central and paraventricular nucleus of the hypothalamus (7), which in turn relays signals to the brainstem, increasing sympathetic outflow.

Despite the wealth of information regarding the central actions of angiotensin II, the cellular signaling events that mediate its effects remain unclear. In this issue of the JCI, Young et al. (8) provide evidence for a unique mechanism of action of this octapeptide. They show that ER stress occurs in the SFO during angiotensin II–induced hypertension and, importantly, that blocking this prevents hypertension (Figure 1).

ER stress and hypertension
The ER is responsible for folding proteins in preparation for their transport through the Golgi and, ultimately, cellular secretion. When unfolded proteins accumulate in

---

Figure 1
Role of central nervous system ER stress in hypertension. Angiotensin II acts on the circumventricular organs, including the subfornical organ (SFO), the organum vasculosum of the lamina terminals (OVLT), the median eminence (ME), and the area postrema (AP). Also shown for orientation are the median preoptic nucleus (MePO), the rostral ventral lateral medulla (RVLM), and the nucleus tractus solitarius (NTS). SON, supraoptic nucleus. In the SFO, angiotensin II promotes ER stress, documented by distension and disorganization of ER cisternae, increased inhibitor of interferon-induced and double-stranded RNA-activated protein kinase (p58IPK), increased C/EBP homologous protein (CHOP), and phosphorylation of PKR-like endoplasmic reticulum kinase (PERK). ER stress causes dissociation of 78 kDa glucose-regulated protein (GRP78) from PERK, inositol requiring protein (IRE-1), and activating reticulum factor-6 (ATF-6). Ultimately, ER stress in the SFO leads to increased sympathetic outflow and hypertension. Local administration of thapsigargin (TG), which also promotes ER stress, mimics these effects. Treatment with the chemical chaperone tauroursodeoxycholic acid (TUDCA) or overexpression of GRP78 prevents ER stress in the SFO and abrogates angiotensin II–induced hypertension.
excess of the ER’s capacity, an unfolded protein response (UPR) is activated to restore homeostasis. The UPR involves expansion of ER membranes, accelerated degradation of unfolded proteins, increased translation of folding chaperones, and decreased transcription and translation of most other proteins. The UPR is initiated by activation of three ER transmembrane proteins: inositol-requiring enzyme 1 (IRE-1), protein kinase R-like ER kinase (PERK), and activating transcription factor-6 (ATF-6) (9). In unstressed cells, IRE-1, PERK, and ATF-6 bind to the chaperone GRP78, also known as binding immunoglobulin protein, or BiP. Upon UPR activation, GRP78 dissociates from these ER transmembrane proteins, initiating the UPR. Extended activation of the UPR is termed “ER stress” and can result in promotion of proapoptotic pathways mediated by proteins such as caspases, C/EBP homologous protein (CHOP), and JNK. Thus, the UPR and ER stress pathways exquisitely control cell fate decisions. Overactivation of ER stress contributes to diseases such as diabetes, viral infections, neurodegeneration, and cancer (reviewed in ref. 10).

Young et al. demonstrate upregulation of many ER stress pathway members in the SFO during development of hypertension, including GRP78, PERK, CHOP, and p58IPK (8). The last of these is a noncanonical ER stress protein that appears to act as a co-chaperone with GRP78 to promote degradation of translationally stalled polypeptides, preventing their ER accumulation (11, 12). Using electron microscopy, the authors demonstrated that angiotensin II infusion causes ER membrane distension. Most importantly, Young et al. showed that inhibition of ER stress either by the chemical chaperone TUDCA or by local injection of an adenosine expressing GRP78 (AdGRP78) prevented angiotensin II–induced hypertension. Thus, hypertension can be added to the list of diseases to which ER stress is a known contributor.

Stressing the details

One conundrum in studying the UPR is that both pro-survival and pro-death signals can be indiscriminately activated, and the fine-tuned mechanisms by which cell fate is determined are not well understood. This is relevant to the work by Young et al., because other biological stressors might also activate ER stress pathways to generate neuronal signals. It is possible that the timing of events for ER stress pathway regulation is important for the balance of life and death such that pathways activated early in the UPR promote cell survival, while those activated later lead to cell death. This temporal regulation has potential implications for the studies by Young et al. Their data show that p58IPK and p-PERK are upregulated at 7 days after angiotensin II infusion, while GRP78 and CHOP are upregulated at 14 days after infusion (8). A thorough analysis of the temporal regulation of all components of the UPR could provide insight into the homeostatic role of ER stress in the SFO response to angiotensin II.

While Young et al. present clear evidence for a role of SFO-localized ER stress in hypertension, several intriguing questions persist. Importantly, it is not clear how or why angiotensin II would initiate such a response and whether ER stress is actually mediated by the UPR in this setting. Several years ago, this same group made the important discovery that the superoxide radical mediates the effect of angiotensin II in the circumventricular organs (13). Their subsequent work showed that superoxide promotes neuronal calcium influx in response to angiotensin II (14). Indeed, the authors found that angiotensin II–induced superoxide production was blocked by TUDCA in freshly dispersed cells of the SFO and by AdGRP78 in the intact SFO. These findings suggest that ER stress might be upstream of oxidant stress in hypertension. In addition, ER stress is often associated with autophagy (15), and the relevance of this for cells in the SFO is unknown. Finally, ER stress in pathological settings is usually associated with apoptotic cell death. While Young et al. demonstrate upregulation of CHOP in the SFO of hypertensive mice, it is not clear which cells in the SFO are undergoing ER stress, or whether specific cell populations are dying.

Conclusions

In summary, the study by Young et al. provides us with a new paradigm, indicating that ER stress contributes to neuronal activation, the effects of angiotensin II, and the pathogenesis of hypertension. An obvious implication is that despite extensive study, we still do not understand the etiology of so-called essential hypertension, which affects 30% of the Western population and is a major cause of stroke, myocardial infarction, and heart failure. The idea that ER stress might be involved provides new avenues for investigation and may lead to new therapeutic approaches for this disease.

Acknowledgments

This work is supported by NIH R01-HL039006, P01-HL058000, P01-HL095070, P01GM015431, R01-HL105294-02, R01-HL089466, R21DK95456, American Diabetes Association 7-11-AEC-13, and American Heart Association 12EIA827.

Address correspondence to: David G. Harrison, Betty and Jack Bailey Professor of Medicine and Pharmacology, Director of Clinical Pharmacology, Room 536 Robinson Research Building, Vanderbilt University, Nashville, Tennessee 37232-6602, USA. Phone: 615.875.3049; Fax: 615.875.3297; E-mail: david.g.harrison@vanderbilt.edu.


Downloaded from http://www.jci.org on January 8, 2018. https://doi.org/10.1172/JCI65173